Immunization with recombinant class 1 outermembrane protein from Neisseria meningitidis: Influence of liposomes and adjuvants an antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci

Microbiology

Volumn 144, Issue 11, 1998, Pages 3027-3037

  Christodoulides, Myron ^a   Brooks, Joy L ^a   Rattue, Elizabeth ^a   Heckels, John E ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adjuvant; Antibody avidity; Liposome; Neisseria meningitidis; Vaccine

Indexed keywords

ADJUVANT; LIPOSOME; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL GENE; BACTERIAL IMMUNITY; BINDING KINETICS; ESCHERICHIA COLI; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; MOLECULAR CLONING; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MENINGOCOCCUS; NEGIBACTERIA; NEISSERIA MENINGITIDIS;

EID: 0031736406     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/00221287-144-11-3027     Document Type: Article

References (46)

1. Achtman, M., Wall. R. A., Bopp, M., Kusecek, B., Morelli, G., Saken, E. & Hassanking, M. (1991). Variation in class 5 protein expression by serogroup A meningococci during a meningitis epidemic. J Infect Dis 164, 375-382.
2. Barlow, A. K., Heckels, J. E. & Clarke, I. N. (1989). The class 1 outer membrane protein of Neisseria meningitidis: gene sequence and structural and immunological similarities to gonococcal porins. Mol Microbiol 3, 131-139.
3. Bjune, G., Hoiby, E. A., Gronnesby, J. K. & 14 other authors (1991). Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093-1096.
4. Boslego. J., Garcia, J., Cruz, C. & 11 other authors (1995). Efficacy, safety, and immunogenicity of a meningococcal group B (15-P1.3) outer-membrane protein vaccine in Iquique, Chile. Vaccine 13, 821-829.
5. Braun, D. G., van Hoogevest, P. & Schumann, G. (1995). Muramyl tripeptide-phosphatidylethanolamine: a muramyl dipeptide derivative with lipophilic properties. In The Theory and Practical Application of Adjuvants, pp. 213-238. Edited by D. E. S. Stewart-Tull. Chichester: Wiley.
6. Byars, N. E. & Allison, A. C. (1987). Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine 5, 223-228.
7. Carbonare, S. B., Arslanian, C., Silva, M. M., Farhat, C. K. & Carneirosampaio, M. S. (1995). The antimeningococcal vaccine VA-MENGOC-BC induced poor serum and salivary antibody-response in young Brazilian children. Pediatr Infect Dis J 14, 797-803.
8. Christodoulides, M., McGuinness, B. T. & Heckels, J. E. (1993). Immunisation with synthetic peptides containing epitopes of the class 1 outer membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunisation with a cyclic peptide. J Gen Microbiol 139, 1729-1738.
9. Claassen, I., Meylis, J., van der Ley, P. & 9 other authors (1996). Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14, 1001-1008.
10. Cryz, S. J., Que, J. U. & Gluck, R. (1996). A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 14, 1381-1383.
11. Demoraes, J. C., Perkins, B. A., Camargo, M. C. C. & 9 other authors (1992). Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340, 1074-1078.
12. Finne, J., Leinonen, M. & Makela, P. H. (1983). Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet ii, 355-357.
13. Frasch, C. E. & Robbins, J. D. (1978). Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med 147, 629-644.
14. Frasch, C. E., Zollinger, W. D. & Poolman, J. T. (1985). Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7, 504-510.
15. Fries, L. F., Gordon, D. M., Richards, R. L., Egan, J. E., Hollingdale, M. R., Gross, M., Silverman, C. & Alving, C. R. (1992). Liposomal malaria vaccine in humans - a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 89, 358-362.
16. Goldschneider. I., Gotschlich, E. C. & Artenstein, M. S. (1969). Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129, 1307-1326.
17. Gregoriadis, G. (1995). Liposomes as immunological adjuvants. In The Theory and Practical Application of Adjuvants, pp. 145-169. Edited by D. E. S. Stewart-Tull. Chichester: Wiley.
18. Hermanson, G. T., Mallia, A. K. & Smith, P. K. (1992). Immobilised Affinity Ligand Techniques. London: Academic Press.
19. Hoffman, S. L., Edelman, R., Bryan, J. P. & 13 other authors. (1994). Safety, immunogenicity and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell-wall skeleton of mycobacteria, and squalane as adjuvant. Am J Trop Med Hyg 51, 603-612.
20. Hunter, R., Olsen, M. & Buynitzky, S. (1991). Adjuvant activity of nonionic block copolymers. 4. Effect of molecular weight and formulation on titer and isotype of antibody. Vaccine 9, 250-256.
21. Idanpaan-Heikkila, I., Hoiby, E. A., Chattopadhyay, P., Airaksinen, U., Michaelsen, T. M. & Wedege, E. (1995). Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J Med Microbiol 43, 335-343.
22. Jiskoot, W., Teerlink, T., Van Hoof, M. M. M., Bartels, K., Kanhai, V., Crommelin, D. J. & Beuvery, E. C. (1986). Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexes. Infect Immun 54, 333-338.
23. Jonsson, U., Fagerstam, L., Ivarsson, B. & 13 other authors (1991). Real-time biospecific interaction analysis using surface-plasmon resonance and a sensor chip technology. Biotechniques 11, 620-627.
24. Karlsson, R., Michaelsson, A. & Mattsson, L (1991). Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 145, 229-240.
25. van der Ley, P., Heckels, J. E., Virji, M., Hoogerhout, P. & Poolman, J. T. (1991). Topology of outer membrane porins in pathogenic Neisseria spp. Infect Immun 59, 2963-2971.
26. van der Ley, P., van der Biezen, J. & Poolman, J. T. (1995). Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13, 401-407.
27. McGuinness, B. T., Lambden, P. R. & Heckels, J. E. (1993). Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. Mol Microbiol 7, 505-514.
28. Milagres, L. G., Ramos, S. R., Sacchi, C. T., Melles, C. E. A., Vieira, V. S. D., Sato, H., Brito, G. S., Moraes, J. C. & Frasch, C. E. (1994). Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 62, 4419-4424.
29. Muttilainen, S., Butcher, S. J., Runeberg, K., Nurminen, M., Idanpaan-Heikkila, I., Wahlstrom, E. & Sarvas, M. (1995a). Heterologous production of the P1 porin of Neisseria meningitidis in Bacillus subtilis: the effect of an N-terminal extension on the presentation of native-like epitopes. Microb Pathog 18, 365-371.
30. Muttilainen, S., Idanpaan-Heikkila, I., Wahlstrom, E., Nurminen, M., Makela, P. H. & Sarvas, M. (1995b). The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes. Microb Pathog 18, 423-436.
31. Nurminen, M., Butcher, S., Idanpaan-Heikkila, I., Wahlstrom, E., Muttilainen, S., Runeberg-Nyman, K., Sarvas, M. & Makela, P. H. (1992). The class 1 outer membrane protein of Neisseria meningitidis produced in Bacillus subtilis can give rise to protective immunity. Mol Microbiol 6, 2499-2506.
32. Peeters, C. C. A. M., Rumke, H. C., Sundermann, L. C., van der Voort, E. M. R., Meulenbelt, J., Schuller, M., Kuipers, A. J., van der Ley, P. & Poolman, J. T. (1996). Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14, 1009-1015.
33. Perkins, B. A., Jonsdottir, K., Briem, H. & 16 other authors (1998). Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 177, 683-691.
34. Quan, W. D. Y., Dean, G. E., Spears, L, Spears, C. P., Groshen, S., Merritt, J. A. & Mitchell, M. S. (1997). Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus Saf-M. J Clin Oncol 15, 2103-2110.
35. Rosenqvist, E., Hoiby, E. A., Wedege, E., Bryn, K., Kolberg, J., Klem, A., Ronnild, E., Bjune, G. & Nokleby, H. (1995). Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63, 4642-4652.
36. Rudbach, J. A., Johnson, D. A. & Urlich, J. T. (1995). Ribi adjuvants: chemistry, biology and utility in vaccines for human and veterinary medicine. In The Theory and Practical Application of Adjuvants, pp. 287-314. Edited by D. E. S. Stewart-Tull. Chichester: Wiley.
37. Schultz, N., Oratz, R., Chen, D. L., Zeleniuchjacquotte, A., Abeles, G. & Bystryn, J. C. (1995). Effect of Detox as an adjuvant for melanoma vaccine. Vaccine 13, 503-508.
38. Tinsley, C. R. & Heckels, J. E. (1986). Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection. J Gen Microbiol 132, 2483-2490.
39. Tsai, C. M., Frasch, C. E. & Mocca, L. F. (1981). Five structural classes of major outer-membrane proteins in Neisseria meningitidis. J Bacteriol 146, 69-78.
40. Van Cott, T. C., Bethke, F. R., Polonis, V. R., Gorny, M. K., Zollapazner, S., Redfield, R. R. & Birx, D. L. (1994). Dissociation rate of antibody-gp 120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol 153, 449-459.
41. Verma, J. N., Rao, M., Amselem, S., Krzych, U., Alving, C. R., Green, S. J. & Wassef, N. M. (1992). Adjuvant effects of liposomes containing Lipid A - enhancement of liposomal antigen presentation and recruitment of macrophages. Infect Immun 60, 2438-2444.
42. van der Voort, E. R., van der Ley, P., van der Biezen, J., George, S., Tunnela, O., van Dijken, H., Kuipers, B. & Poolman, J. (1996). Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 64, 2745-2751.
43. Ward, S. J., Scopes, D. A., Christodoulides, M., Clarke, I. N. & Heckels, J. E. (1996). Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response. Microb Pathog 21, 499-512.
44. Wedege, E. & Froholm, L. O. (1986). Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 51, 571-578.
45. Wetzler, L. M., Blake, M. S. & Gotschlich, E. C. (1988). Characterization and specificity of antibodies to protein I of Neisseria gonorrhoeae produced by injection with various protein I-adjuvant preparations. J Exp Med 168, 1883-1897.
46. White, D. A., Barlow, A. K., Clarke, I. N. & Heckels, J. E. (1990). Stable expression of meningococcal class 1 protein in an antigenically reactive form in outer membranes of Escherichia coli. Mol Microbiol 4, 769-776.